Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LRMR Larimar Therapeutics	$3.56 -2.1%	$3.84	$2.71 ▼ $6.42	$369.50M	0.83	2.99 million shs	1.16 million shs
LXEO Lexeo Therapeutics	$4.69 -4.2%	$5.32	$3.60 ▼ $10.99	$367.71M	1.38	935,078 shs	462,439 shs
SXTC China SXT Pharmaceuticals	$2.47 -3.0%	$1.88	$1.25 ▼ $1,046.98	$94.21M	1.91	191,866 shs	13,222 shs
XFOR X4 Pharmaceuticals	$3.94 -3.8%	$4.09	$1.35 ▼ $4.83	$373.04M	0.34	443,562 shs	355,560 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LRMR Larimar Therapeutics	-1.36%	+2.54%	+5.22%	-25.15%	+21.40%
LXEO Lexeo Therapeutics	-1.01%	-1.81%	-4.31%	-13.45%	+16.15%
SXTC China SXT Pharmaceuticals	+2.42%	+14.41%	+57.76%	+92.42%	-99.06%
XFOR X4 Pharmaceuticals	+2.25%	+0.99%	+1.24%	-5.10%	+77.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LRMR Larimar Therapeutics	$3.56 -2.1%	$3.84	$2.71 ▼ $6.42	$369.50M	0.83	2.99 million shs	1.16 million shs
LXEO Lexeo Therapeutics	$4.69 -4.2%	$5.32	$3.60 ▼ $10.99	$367.71M	1.38	935,078 shs	462,439 shs
SXTC China SXT Pharmaceuticals	$2.47 -3.0%	$1.88	$1.25 ▼ $1,046.98	$94.21M	1.91	191,866 shs	13,222 shs
XFOR X4 Pharmaceuticals	$3.94 -3.8%	$4.09	$1.35 ▼ $4.83	$373.04M	0.34	443,562 shs	355,560 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LRMR Larimar Therapeutics	-1.36%	+2.54%	+5.22%	-25.15%	+21.40%
LXEO Lexeo Therapeutics	-1.01%	-1.81%	-4.31%	-13.45%	+16.15%
SXTC China SXT Pharmaceuticals	+2.42%	+14.41%	+57.76%	+92.42%	-99.06%
XFOR X4 Pharmaceuticals	+2.25%	+0.99%	+1.24%	-5.10%	+77.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LRMR Larimar Therapeutics	3.10	Buy	$13.50	279.75% Upside
LXEO Lexeo Therapeutics	2.89	Moderate Buy	$18.75	300.21% Upside
SXTC China SXT Pharmaceuticals	1.00	Sell	N/A	N/A
XFOR X4 Pharmaceuticals	2.50	Moderate Buy	$9.38	138.25% Upside

Current Analyst Ratings Breakdown

Latest SXTC, XFOR, LXEO, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2026	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $9.00
6/23/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/11/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/5/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/4/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/2/2026	XFOR X4 Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$12.00
5/29/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/27/2026	LRMR Larimar Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$9.00
5/22/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/19/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
5/18/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$13.00 ➝ $12.00

(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A
SXTC China SXT Pharmaceuticals	$1.74M	54.15	N/A	N/A	$3,187.45 per share	0.00
XFOR X4 Pharmaceuticals	$35.11M	10.57	N/A	N/A	$2.13 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LRMR Larimar Therapeutics	-$165.67M	-$2.06	N/A	N/A	N/A	N/A	-134.14%	-96.00%	8/13/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.45	N/A	N/A	N/A	N/A	-47.48%	-41.72%	8/13/2026 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	-$79.20M	-$4.54	N/A	N/A	N/A	-1,106.30%	-94.90%	-48.09%	8/6/2026 (Estimated)

Latest SXTC, XFOR, LXEO, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2026	Q1 2026	LRMR Larimar Therapeutics	-$0.53	-$0.31	+$0.22	-$0.31	N/A	N/A
5/11/2026	Q1 2026	LXEO Lexeo Therapeutics	-$0.29	-$0.25	+$0.04	-$0.25	N/A	N/A
5/6/2026	Q1 2026	XFOR X4 Pharmaceuticals	-$0.20	-$0.16	+$0.04	-$0.16	$3.20 million	$2.71 million
3/30/2026	Q4 2025	LXEO Lexeo Therapeutics	-$0.32	-$0.27	+$0.05	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LRMR Larimar Therapeutics	N/A	4.29	4.29
LXEO Lexeo Therapeutics	N/A	14.16	14.16
SXTC China SXT Pharmaceuticals	N/A	4.37	4.24
XFOR X4 Pharmaceuticals	0.45	10.18	9.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LRMR Larimar Therapeutics	91.92%
LXEO Lexeo Therapeutics	60.67%
SXTC China SXT Pharmaceuticals	5.02%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
LRMR Larimar Therapeutics	4.50%
LXEO Lexeo Therapeutics	2.00%
SXTC China SXT Pharmaceuticals	3.95%
XFOR X4 Pharmaceuticals	1.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LRMR Larimar Therapeutics	30	103.88 million	99.21 million	Optionable
LXEO Lexeo Therapeutics	58	78.52 million	76.95 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	38.22 million	36.71 million	Not Optionable
XFOR X4 Pharmaceuticals	80	94.32 million	93.25 million	No Data

SXTC, XFOR, LXEO, and LRMR Headlines

Recent News About These Companies

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026 | globenewswire.com

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 27, 2026 | globenewswire.com

How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress

May 21, 2026 | finance.yahoo.com

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

May 20, 2026 | zacks.com

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

May 18, 2026 | zacks.com

Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now

May 15, 2026 | finance.yahoo.com

Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now

May 14, 2026 | insidermonkey.com

Guggenheim Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)

May 11, 2026 | theglobeandmail.com

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

May 6, 2026 | zacks.com

X4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI®

May 6, 2026 | quiverquant.comQ

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026 | globenewswire.com

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

April 29, 2026 | globenewswire.com

One X4 Pharmaceuticals Insider Raised Their Stake In The Previous Year

April 9, 2026 | finance.yahoo.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2026 | globenewswire.com

X4 Pharmaceuticals (XFOR) price target increased by 25.00% to 11.90

March 27, 2026 | msn.com

X4 Jumps on Q4 Figures

March 17, 2026 | baystreet.ca

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

March 17, 2026 | zacks.com

X4 Pharmaceuticals Reports Positive EMA Opinion on Mavorixafor and Updates on 4WARD Phase 3 Trial Enrollment Progress

March 17, 2026 | quiverquant.comQ

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 17, 2026 | globenewswire.com

Guggenheim initiates coverage of X4 Pharmaceuticals (XFOR) with buy recommendation

March 10, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, XFOR, LXEO, and LRMR Company Descriptions

Larimar Therapeutics NASDAQ:LRMR

$3.56 -0.08 (-2.07%)

As of 02:54 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Lexeo Therapeutics NASDAQ:LXEO

$4.68 -0.21 (-4.19%)

As of 02:53 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

China SXT Pharmaceuticals NASDAQ:SXTC

$2.46 -0.08 (-2.95%)

As of 02:02 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

X4 Pharmaceuticals NASDAQ:XFOR

$3.94 -0.16 (-3.79%)

As of 02:54 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, XFOR, LXEO, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, XFOR, LXEO, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, XFOR, LXEO, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, XFOR, LXEO, and LRMR Company Descriptions

Larimar Therapeutics NASDAQ:LRMR

Lexeo Therapeutics NASDAQ:LXEO

China SXT Pharmaceuticals NASDAQ:SXTC

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, XFOR, LXEO, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, XFOR, LXEO, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, XFOR, LXEO, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, XFOR, LXEO, and LRMR Company Descriptions

Larimar Therapeutics NASDAQ:LRMR

Lexeo Therapeutics NASDAQ:LXEO

China SXT Pharmaceuticals NASDAQ:SXTC

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools